Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2016 10:45 ET | Source: Medivir AB

Medivirs nukleotidbaserade polymerashämmare för behandling av levercancer, MIV-818, går in i preklinisk utvecklingsfas

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) meddelar idag att MIV-818 har valts som läkemedelskandidat från bolagets projekt med nukleotidbaserade DNA polymerashämmare för behandling av...
November 01, 2016 10:45 ET | Source: Medivir AB

Medivir’s nucleotide polymerase inhibitor for the treatment of liver cancer, MIV-818, enters non-clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV -818 has been selected as a candidate drug (CD) from its nucleotide DNA polymerase inhibitor project for the treatment...
November 01, 2016 03:00 ET | Source: Medivir AB

Medivir divests its pharmaceutical company BioPhausia (Nordic Brands) to Karo Pharma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has entered into an agreement with Karo Pharma AB regarding the sale of Medivir’s subsidiary BioPhausia AB...
November 01, 2016 03:00 ET | Source: Medivir AB

Medivir avyttrar läkemedelsbolaget BioPhausia (Nordic Brands) till Karo Pharma

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) meddelar idag att bolaget träffat avtal om avyttring av Medivirs dotterbolag BioPhausia (Nordic Brands) till Karo Pharma AB. Köpeskillingen uppgår till...